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ABSTRACT 
T-type Calcium channels (TTCCs) are key regulators of membrane excitability, reason why TTCC 
pharmacology is subject to intensive research in the neurological and cardiovascular fields. TTCC also play a 
role in cancer physiology, and pharmacological blockers such as tetralols and dihydroquinazolines reduce 
the viability of cancer cells in vitro and slow tumor growth in murine xenografts. However, available 
compounds are better suited to block TTCC in excitable membranes rather than TTCC contributing window 
currents at steady potentials. Consistently, tetralols and dihydroquinazolines exhibit cytostatic/cytotoxic 
activities at higher concentrations than those required for TTCC block, which may involve off-target effects. 
Gene silencing experiments highlight the targetability of TTCC, but further pharmacological research is 
required for TTCC block to become a chemotherapeutic option.  
Physiological and pathophysiological roles of TTCC 
Voltage-gated Ca2+ channels (Cav channels, see Glossary) constitute the only biological transducers of
electrical into biochemical signals (cytosolic Ca2+ elevations) that initiate multiple physiological events. 
There are 10 members of the Cav family in mammals, that are classified into 3 subfamilies based on 
sequence homology: Cav1, Cav2 and Cav3 [1]. In a simplified view, Cav channels can adopt 3 conformational 
states: resting-deactivated (closed and sensitive to depolarizing stimuli), activated (open) and inactivated 
(non-conducting and refractory to depolarizing stimuli) [2]. Forward/backward transitions between these 
states (called gating) are time- and voltage- or state-dependent (Figure 1A, B). By virtue of their distinctive 
2 
 
biophysical properties, i.e. activation near resting membrane potentials (low voltage-activation, LVA) and 
slow deactivation kinetics, the 3 members of the Cav3 subfamily (T-type Ca
2+ channels, TTCC) are suited for 
amplifying small depolarizations of the membrane and mediating Ca2+ oscillations [3][4][5]. Indeed, the 
expression of TTCC was initially related to membrane excitability, such as neuron oscillatory firing [6][7] 
and cardiac pacemaker potentials [8]. More recently, abnormalities in TTCC function or expression levels in 
neurons have been linked to tremor [9], absence seizures [10], spinocerebellar ataxia [11][12][13], 
different types of epilepsies [14] and visceral or neuropathic pain pathophysiology [15][16][17][18][19]. 
Correspondingly, pharmacological targeting of TTCC has shown effectiveness in preclinical models of pain 
(reviewed in [20]) and epilepsy (reviewed in [14]), by reducing hyperexcitability. Nonetheless, TTCC provide 
a key pathway for Ca2+ entry near the resting membrane potential, and display an augmented expression 
during the G1-S transition in non-excitable cells [21][22][23][24][25][26][27]. During this period both the 
availability of TTCC and the driving force for Ca2+ entry are also expected to increase, because the plasma 
membrane is hyperpolarized in correspondence with the overexpression of different types of K+ channels 
[28]. The existence of a sustained Ca2+ influx through voltage-gated channels relies on the overlap between 
steady-state activation and inactivation, a phenomenon known as window currents (Figure 1C). Window 
currents are estimated to be contributed by ~1 % of TTCC present in the membrane, involving a low-level 
Ca2+ entry which may be physiologically relevant because TTCC are strategically located in microdomains 
and associated with signaling complexes [29][30]. Cancer cells viability depends on TTCC function 
[31][32][33][34], reason why TTCC pharmacological block is a tentative chemotherapeutic strategy (see 
Clinician Corner). TTCC “hyperactivation” has been attempted as an alternative approach to dysregulate 
Ca2+ homeostasis/signaling in cancer cells. The green tea polyphenol epigallocathechin-3-gallate (EGCG) 
proved cytotoxic to cultured mesothelioma [35] and breast cancer [36] cells by a mechanism involving 
reactive oxygen species (ROS) production and subsequent activation of Cav3.2 channels. However, at the 
concentrations used in these studies EGCG is known to target several proteins involved in tumor 
progression [37], so that currently TTCC block remains the strategy of choice from the viewpoint of 
specificity.  
 
Block of voltage-gated channels is often state-dependent 
Different electrophysiological protocols have been developed to study the pharmacological interaction and 
blocking mechanism of several Nav and Cav channel blockers, which are determinant for their therapeutic 
profiles. The term use-dependent block refers to the positive correlation between frequency of stimulation 
(i.e. membrane depolarizing stimuli) and degree of block, thus it is suggestive of drug binding to open 
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and/or inactivated channels. The desired selectivity of local anesthetics, antiarrhythmic and anticonvulsant 
drugs for excitable membranes is based on their preferential interaction with Nav (or Cav) channels in these 
gating states, which are promoted by repetitive firing of action potentials [38]. On the contrary, tonic block 
is experimentally assessed by low-frequency stimulation and is attributable to binding to resting channels. 
Additional criteria have been proposed to evaluate the state-dependence of block: increased blocking 
potency at depolarized holding potentials, slowing of recovery from inactivation, and hyperpolarizing shift 
of the steady-state inactivation curve, have been interpreted as preferential binding and selective 
stabilization of the inactivated states [39]. Based on these and other electrophysiological procedures, most 
tested Nav/Cav blockers have shown to display a higher affinity for channels in their resting or  inactivated 
states from the perspective of the modulated receptor theory [40][41]. This feature is likely to hinder the 
block of the fraction of channels contributing window currents, which are permanently open.  
 
The issue of selectivity  
Na+ and Ca2+ channel inhibitors have long been applied in clinical practice to tackle diverse cardiovascular 
and neurological conditions. A number of dihydropyridines, phenylalkylamines and benzodiazepines are 
used as antihypertensives and antiarrythmics because they promote vasodilation and/or negative inotropic 
or chronotropic effects. Albeit initially these compounds were regarded as selective for Nav or L-type Cav 
channels (LTCC), eventually interactions with different ion channels including TTCC were described for 
many of them [42]. Similarly, diphenylbutylpiperidines, diphenylpiperazines, succinimides and 
trimethiadones, originally used as neuroleptics/antiepileptics based on dopamine receptor or Nav 
antagonism, were later reported to exert TTCC block [43]. Arachnid neurotoxins [44][45] and endogenous 
modulators such as endocannabinoids were also found to target TTCC among other channels [46]. In the 
last 10 years the arsenal of TTCC modulators has been extended with the development of new agents 
pursuing TTCC selective block, mainly in the context of pain research [47][48][49]. However, all voltage-
gated channels are traced back a common ancestor and display structural homology, and the finding of 
bona fide TTCC (or TTCC-isoform) selective blockers is challenging.  
 
TTCC blockers are cytotoxic to cancer cells at supramaximal concentrations 
Most widely used TTCC blockers in cancer research are membrane-permeable benzimidazolyl-substituted 
tetraline derivatives of phenylalkylamines (tetralols), dihydroquinazoline derivatives (DHQ) and 
diphenylbutylpiperidine pimozide. Some of these compounds have been tested in preclinical in vivo 
models, in which have shown to slow tumor growth (see [50] for a recent review).  
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Mibefradil was released in 1997 as a long-acting Ca2+ channel blocker for the management of ischemia, 
angina and cardiac arrhythmias. Its protective actions and lack of negative inotropic effects were attributed 
to a selectivity for TTCC over LTCC [51][52][53][54]. Analogues of mibefradil have been synthetized by 
replacing a methoxyacetyl esther with more lipophilic groups, in order to limit cytoplasmic hydrolysis, and 
NNC-55-0396 was distinguished by its potent and selective TTCC blocking properties [24][55].  
Both mibefradil and NNC-55-0396 exert a poorly reversible block consistent with a high affinity binding to 
the inactivated state, and it is suggested that the drug binding site/s reside within transmembrane domains 
[56][57][58][59][60]. A slow onset seems to be behind notable discrepancies for reported blocking 
potencies [55]. Other reasons for discrepant inhibitory concentration 50 (IC50) values are the variable 
voltage protocols and recording conditions used for measuring TTCC currents, such that blockade is 
enhanced at depolarized holding potentials and low Ca2+ solutions [58]. Potency is also affected by 
temperature, such that the IC50 for mibefradil on Cav3.2 channels expressed in HEK293 cells increased up to 
5-fold at 35°C compared to room temperature, from 139 to 792 nM [58]. Assuming this variability, 
significantly lower IC50 values on TTCC compared to the effective/growth inhibition concentrations 
(EC50/GI50) against cancer cells, can still be observed for tetralols (Table 1). In excitable membranes, gating 
of TTCC occurs with action potential firing, and TTCC experience all possible conformational states, so that 
high-affinity drug binding to the non-conducting states will prevent channel opening most efficiently. 
However, at steady, depolarized potentials typical of cancer cells [61], the only TTCC achieving the open 
state are a small fraction of inactivation-resistant channels contributing window currents, for which drug 
potency is reduced (Figure 1). In line with this rationale, phasic use-dependent block of Cav3.2 channels by 
mibefradil was considerably more potent than tonic block [60][62]. Similarly, block of Cav3.1 by NNC-55-
0396 demonstrated partial relief at hyperpolarized potentials and was enhanced by increasing the 
frequency of stimulation [60]. In fact, the influence of tetralols on the magnitude of window currents is 
enigmatic. Gomora et al. showed that in adrenocortical cells, mibefradil shifted the voltage-dependence of 
steady-state inactivation of TTCC by -5.7 mV, without changing the voltage-dependence of channel opening 
[63], an effect that would minimize window currents. Nonetheless, the steady-state inactivation of TTCC 
currents recorded in DRG neurons [64] and in HEK293 expressing Cav3.2 channels [55][65] was flattened by 
mibefradil and NNC-55-0386, respectively, increasing the area of overlap with activation voltage ranges. 
Calculation of channel availability as the product of steady-state inactivation and activation curves, shows 
that increasing the slope factor for steady-state inactivation may counteract a blocking effect in the voltage 
range for window currents (Box 1).  
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In 2004 Lee et al. evaluated the blocking properties of a series of 3,4-DHQ against recombinant Cav3.1 and 
Cav3.2 channels, and one of the compounds was disclosed as equipotent and more selective when 
compared with mibefradil [66]. This work was followed by structure-activity relationship studies that led to 
the synthesis of other DHQ able to block TTCC, which demonstrated acute toxicity on cultured cancer cells 
at supramaximal concentrations [67][68][69]. In the latter work, KYS05090 had an additional analgesic 
effect in acetic acid-induced writhing test, that was further proved in mouse models of neuropathic and 
neuroinflammatory pain [70]. These studies were further extended with the testing of new DHQ in ovarian 
cancer [71] and lung adenocarcinoma cells [72]. Again, the concentrations required for channel inhibition 
and cytotoxic effects were discrepant, with IC50 values 4-30 fold smaller than GI50 values (Table 1). The 
scant information available for DHQ points nonetheless to a use-dependent block of TTCC, similarly to 
tetralols. KYS0590 and a series of fluoro-substituted DHQ shifted the voltage-dependence of inactivation of 
recombinant Cav3.2 channels toward negative potentials, suggesting the interaction with the inactivated 
states [70][73].  
Anti-psychotic drug pimozide has shown tumoricidal activity in a wide rage of cancer cells (at M 
concentrations) and in mouse xenografts, but its actions are principally attributed to inhibition of 
dopamine, serotonin, epinephrine and sigma receptors (reviewed in [74]). With regards to TTCC, pimozide 
and analogs exert a potent state-dependent block on the three isoforms (at nM concentrations), indicative 
of a preferential binding to the inactivated states [43], similarly to tetralols and DHQ. 
 
On-target vs off-target effects of TTCC blockers on cancer cells viability 
From the perspective of TTCC contribution to G1-S progression, it would be expected that TTCC block 
would reduce cancer cell viability by decreasing cytosolic Ca2+ oscillations/concentration. However, 
anticancer effects of tetralols and DHQ include dysregulation of key homeostatic processes and induction 
of caspase-dependent apoptosis (Table 2), for which on-target effects are not obvious.  
Analysis of cytotoxic effects becomes de facto complex when considering that higher drug concentrations 
associate to a higher risk of off-targeting. Notorious examples are the reported membrane potential shifts, 
hardly owed to TTCC block. Nilius et al. described that mibefradil at 10 μM hyperpolarized the membrane 
potential of calf pulmonary artery endothelial cells by ~13 mV, an effect that was attributed to blockade of 
Ca2+-dependent Cl- channels [75]. In contrast, 10 M mibefradil depolarized the plasma membrane of 
smooth muscle cells [76], human lens epithelial cells [77] and glioma initiating cells [78]. At M 
concentrations mibefradil has been shown to block different types of voltage-gated Ca2+ channels 
[79][80][60] and K+ channels [81][82][83][84][85][86][87], including oncogenic Kv10.1 channels [88], and to 
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activate K(Ca) channels [83] and TRPM7 channels [89]. Of note, K+ channels block or cation-permeable 
TRPM7 channels activation would depolarize membrane potential, whereas activation of K(Ca) channels 
would exert a hyperpolarizing effect. We can envisage two different scenarios for Ca2+ entry depending on 
tetralol influence on membrane potential: (1) hyperpolarization would involve increased TTCC window 
currents in most cancer cells (holding membrane potentials > -40 mV), and increased driving force for Ca2+ 
entry; (2) depolarization would result in reduction of TTCC window currents, but also increased Ca2+ entry 
through activation of high voltage-activated (HVA) Ca2+ channels (Box 2). HVA Cav channels, shown to 
contribute window currents in neurons [90], are widely expressed in cancer cells [91]. Membrane 
depolarization may also negatively affect the electrochemical gradient necessary to extrude Ca2+ by the 
Na+/Ca2+ antiporter, thereby limiting Ca2+ export [78]. Indeed, a clear picture is emerging that the 
biochemical pathways and cellular processes triggered by exposure to tetralols are consistent with 
elevations of cytosolic Ca2+ (Table 2). Other off-target effects point to this direction: in the early years after 
mibefradil synthesis, Eberhard et al. described that at concentrations above 10 M mibefradil mobilized 
Ca2+ from inositol-3-phosphate-sensitive intracellular Ca2+ stores in rat cardiac fibroblasts and human 
platelets [92]. More recently, mibefradil or NNC-55-0396 exposure increased intracellular Ca2+ levels by 
inducing ER calcium release in Jurkat leukaemic T cells [93]. It should be noted that Ca2+-dependent 
pathways may promote cell proliferation and/or survival, instead of cell death [94][95][96].  
Targets other than TTCC have not been thoroughly investigated for DHQ, beyond reports of a generally less 
potent inhibitory action on N-type Cav2.2 channels exerted by some derivatives [72][73][97], although the 
mechanisms involved in the reduction of cell viability appear to be different from tetralols (Table 2). Rim et 
al. concluded that supramaximal concentrations of KYS05047 induced G1 phase cell cycle arrest by 
decreasing intracellular Ca2+ levels [98]. In contrast, KYS05090 led to autophagy and apoptosis of A549 cells 
through generation of ROS, by inhibiting glucose uptake [99]. Events upstream of oxidative stress were not 
investigated but, intriguingly, the authors observed that, although KYS05090 progressively decreased 
cytosolic Ca2+ levels in a time span of 150 min, this feat was not directly related with KYS05090-induced cell 
death.   
 
Effects of gene knockout/knockdown 
Gene silencing has demonstrated the specificity of TTCC pharmacological block in mice models of 
neurological disorders. Consistently, amide TTA-A2 promoted slow-wave sleep in wild-type mice but not in 
mice lacking Cav3.1 and Cav3.3 [100], did not prevent tonic seizures in Cav3.1 knockout (KO) mice [101], and 
its antinociceptive effect on formalin-induced mechanical hypersensitivity was lost in Cav3.2 KO mice [102]. 
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Similarly, the analgesic action of DHQ KYS05090 was ablated in Cav3.2 null-mice [70], whereas the 
administration of antisense oligonucleotides against Cav3.2 abrogated the antihyperalgesic effects of 
piperidine TTA-P2 [48] and of mibefradil [55] in diabetic rats, in tune with a prominent role for this isoform 
in nociception. 
Similar approaches have not been attempted in cancer research. Sparse data indicates that in vitro 
knockdown of TTCC leads to cell cycle arrest and/or apoptosis of cancer cells, although the molecular 
pathways linking TTCC downregulation and viability are ill-defined [103][104][105]. Nevertheless, gene 
overexpression/silencing experiments point to the existence of functional differences between Cav3 
isoforms [106], already inferred from the observation of their differential (in some cases complementary) 
expression in various cells/tissues [50].  
 
Concluding Remarks 
TTCC pharmacological targeting is being intensively investigated in the neurological and cancer fields. Most 
blockers target preferentially TTCC in their non-conducting states, and thus appear well-suited to tackle 
TTCC contribution towards (hyper)excitability. In contrast, in cancer cells, TTCC currents are contributed by 
a small population of non-inactivating TTCC, for which currently used blockers display little affinity. Off-
target effects are the price to be paid for low potency block, and they should be thoroughly investigated in 
order to dissect the fundamental functions of TTCC in cancer (see Outstanding Questions). Mibefradil, for 
which clinical trials have been conducted in Glioblastoma Multiforme (GBM) patients, induces membrane 
potential shifts liable to affect Ca2+ fluxes through voltage-dependent and independent channels. Reported 
off-target effects also include Ca2+ mobilization, bound to deregulate multifaceted cellular processes like 
the unfolded protein response or macroautophagy [107]. Available data suggests that mibefradil may, in 
fact, induce a paradoxical activation of Ca2+-dependent pathways/cell processes that have negative 
consequences for the viability of cancer cells in vitro and in murine xenografts, but with unknown effects 
on tumor progression in human patients. Thus, we propose the cytotoxic evaluation of potent/highly 
selective state-dependent TTCC blockers developed in the context of neurological research, such as amides 
TTA-A1/TTA-A2, piperidine TTA-P2 [47] or piperazine-based Z941/Z944 [108]. Alternatively and, resting on 
the assertion that potent block of TTCC window currents is achieved by open-channel block, we encourage 
the evaluation of compounds that enhance inactivation kinetics, and/or induce a depolarizing shift of TTCC 
activation, such as some succinimides [109], cannabinoids [110], and gating modifier neurotoxins [45]. An 
additional issue and principal end point is the analysis of functional differences between TTCC isoforms, 
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which is beyond the resolution of current pharmacology and can only be approached by gene knockdown 
strategies.  
 
Clinician’s Corner  
T-type Ca2+ channels (TTCC) play a role in membrane excitability, and increased TTCC function or expression 
levels have been linked to a range of disorders affecting the central and peripheral nervous systems, as well 
as the heart function. TTCC pharmacological targeting is currently an effervescent field of research and, 
notably, there are several recent developments focused in ameliorating neuropathic pain. 
Nonetheless, TTCC provide a key pathway for Ca2+ entry at negative membrane potentials and play a 
pivotal role in cell proliferation. For this reason, repurposing of TTCC blockers for cancer treatment is under 
consideration. The role of TTCC GBM progression has received considerable attention in recent years, and 
cytostatic/cytotoxic effects of TTCC pharmacological blockers described in vitro have given way to studies 
on murine xenografts, and to preliminary clinical trials regarding the safety and optimal dosages of 
tetraline-derivative mibefradil.  
Yet, currently available blockers are not able to discriminate between TTCC isoforms, a relevant distinction 
since they play different physiological roles. Furthermore, most compounds display a higher affinity for 
channels in their resting or inactivated states, and thus are better suited to block TTCC in the context of 
action potential firing rather than at steady membrane potentials. Low-potency block of TTCC by tetralols 
and dihydroquinazolines in cancer cells is likely to underlie their use at supramaximal concentrations 
which, in turn, increases the risk of off-targeting. Off-target effects reported for mibefradil include 
membrane potential shifts and Ca2+ mobilization, with unpredictable consequences at the clinical level. 
Both the pharmacological profile and the cytotoxicity of TTCC blockers recently developed in the context of 
neurological research need to be carefully studied to assess their applicability as chemotherapeutics. Gene 
silencing experiments highlight the value of targeting TTCC against hyperalgesia/allodinia and cancer, but 
pharmaceutical research needs to press ahead to block them in a potent and selective manner, particularly 
in the latter case. 
 
Box 1.  How channel availability depends on steady-state inactivation parameters  
Steady-state inactivation parameters have shown to be modified by drugs targeting TTCC. A 
hyperpolarizing shift of the mid-point for inactivation is bound to reduce channel availability, whereas an 
increase of the k slope factor for inactivation will cause the opposite effect. Both effects have been 
reported for tetralols. Despite scarcity, data available for other blockers including dihydroquinazolines, 
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diphenylbutylpiperidines, diphenylpiperazines and succinimides are also indicative of a hyperpolarizing 
shift of inactivation. Additionally, an increased slope factor for inactivation could  be seen for -methyl--
phenylsuccinimide on Cav3.1 and Cav3.2 channels in [109] and for KYS05090S [70], KCP10060F and 
KCP10067F [73] DHQ on Cav3.2 channels, although these data were not quantified. 
Figure I: Top: normalized steady-state inactivation/activation curves built from data published in [111] 
(black curve), and after shifting the mid-point for inactivation by -5.7 mV, an effect described for mibefradil 
at 1 M on TTCC currents [63] (red curve). In the former work, Boltzmann activation parameters were: V50 
= -49 mV, slope K factor = 4.6 mV; inactivation parameters were: V50 = -74.2 mV, slope k factor = 5.5 mV. In 
the latter work, Boltzmann parameters for activation did not differ significantly in the presence of 
mibefradil, and the slope factor for inactivation was not reported. Bottom: the fraction of open channels 
enabling window currents (channel availability) is calculated as the product between steady-state 
inactivation and activation curves. 
Figure II: Top: normalized steady-state inactivation/activation curves built from data published in [55] 
before (black curve) and after application of NNC-55-0396 at 8 M (red curve). Activation parameters: V50 = 
-32.6 mV and -32.1 mV for controls and cells treated with NNC-55-0396, respectively; slope k factor = 4.2 
mV in control cells and = 4.33 mV cells incubated with NNC-55-0396. Inactivation parameters: V50 = -59.2 
mV and -62.8 mV for controls and cells incubated with NNC-55-0396, respectively; slope k values were 4.9 
mV for controls and 8.0 mV for cells incubated with NNC-55-0396, respectively. Bottom: channel 
availability was calculated as the product between steady-state inactivation and activation curves. Note 
that, in the -50 mV - 0 mV range, the fraction of open channels is considerably higher in the presence of 
NNC-55-0396 (normalized values, left Y axis). Discontinuous blue curve represents the % block necessary to 
null the increase in window currents due to NNC-55-0396-mediated increase in K slope value for steady-
state inactivation (right Y axis).  
 
Box 2. Effects of tetralols on membrane potential and their influence on Ca2+ influx 
Off-target effects associated to the use of mibefradil (and unexplored for other blockers) are either plasma 
membrane hyperpolarization [75] or depolarization [76][78]. In turn, membrane potential shifts are bound 
to affect: (1) TTCC channel availability, that will increase or decrease depending on membrane potential 
values before treatment. A majority of cancer cells display depolarized mean membrane potentials (resting 
between -10 and -50 mV [61]) relative to the peak of window currents measured in 2 mM Ca2+ (between -
50 and -70 mV approximately for Cav3.1 and Cav3.2, see Figure I). Hence, membrane depolarization will 
exponentially reduce and, conversely, hyperpolarization will exponentially increase TTCC window currents. 
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(2) HVA Cav channels availability. By definition, HVA channels activate at higher potentials compared to 
LVA, but steady-state inactivation is also shifted in the positive direction. Inactivation of HVA Cav channels 
depends largely on the assembly of  and 2 accessory subunits with the main pore-forming subunits 
[112][113]. A comparison between Cav3.1 (black curve) and Cav2.3 (+1b + 21) channels (blue curve) 
expressed in HEK293 cells and recorded in 10 mM Ba2+ accounted for +21.2 /+18.2 mV shifts in V50 for 
activation/inactivation [114]. In this example, Cav2.3 window currents will increase exponentially by 
depolarization in the range between -50 and-30 mV. Available data for Cav2.1 channels co-expressed with 
auxiliary 4a and 2 subunits in COS-7 cells, and recorded in 10 mM Ca2+, places midpoints for activation 
and inactivation further depolarized at -1.6 and -21 mV, respectively [115]. Here, membrane depolarization 
will increase Cav2.1 window currents exponentially in the -40 to -10 mV range (green
 curve). (3) Driving 
force for Ca2+ entry, decreasing linearly by depolarization according to Ohm’s law (ICa = (Vm-VCa)* gCa. 
Where ICa is Ca
2+ currents, Vm membrane potential, VCa the equilibrium potential for Ca
2+ and gCa the Ca
2+ 
conductance, (Vm-VCa) the driving force for Ca
2+ entry). These putative actions at multiple levels make 
difficult to predict a net effect of tetralols on Ca2+ homeostasis/signaling.  
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Figure 1: Gating of TTCC and steady-state (window) currents.  
A. Transitions between activated-open (O), closed-deactivated (C) and inactivated (I) states are time- and 
voltage- or state-dependent. Activation is a fast process compared to inactivation. The inactivated state is 
thermodynamically stable and can be achieved from both open and closed states.  
B. TTCC currents elicited by stepping from -100 mV (HP) to -30 mV (TP). Inactivation is evidenced by the 
progressive current decline during TP. Deactivation is observed by the presence of tail currents after TPs.   
C. Voltage protocols for measuring steady-state inactivation and activation, and the respective curves. For 
activation, a range of increasingly depolarizing 50-100 ms TPs is applied from a fixed, negative HP (-70 to -
120 mV), and the amplitude of deactivating tail currents is measured after TPs. For steady-state 
inactivation, long depolarizing prepulses (PP, >1 s) are applied prior to a depolarizing test pulse. Steady-
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state activation/inactivation curves for normalized currents are calculated by fitting data to first-order 
Boltzmann functions. Activation: 𝐼 = 𝐼𝑚𝑎𝑥 /[1 +
exp(𝑉50−𝑉)
𝐾
]. Inactivation: 𝐼 = 𝐼𝑚𝑎𝑥 /[1 +
exp(𝑉−𝑉50)
𝐾
], 
where I is current amplitude, Imax is maximal current amplitude (can be substituted by Gmax or maximal 
conductance), V is membrane potential, V50 is mid-potential for activation/inactivation (at which half of the 
channels are open/inactivated) and K is slope factor (mV/e-fold change). Window currents are defined by 
the voltage range of overlap between the inactivation and activation curves. Panel A, B was reproduced 
from Karmažínová and Lacinová, Physiol. Res. 59 (Suppl. 1): S1-S7, 2010, with permission. Panel C was 
adapted from Trends Pharmacol Sci. 30(1):32-40. Iftinca and Zamponi, 2009, Copyright Elsevier.  
 
Figure 2. Scheme illustrating the conclusions attained in this article 
The state-dependence of most currently available TTCC blockers implies a low potency block of 
inactivation-resistant, permanently-open TTCC expressed in cancer cells. This is evidenced by higher EC50 
values on cancer cells viability, compared to IC50 values on TTCC currents elicited by depolarizing voltage 
steps. The application of high drug concentrations is associated to increased off-target effects, which are 
evidenced by membrane potential shifts and intracellular Ca2+ mobilization upon application of tetralols, 
and that are unexplored for other TTCC blockers. Subsequently, activation of Ca2+-dependent pathways/cell 
processes may lead to reduced cell proliferation or increased cell death observed in vitro, but it could be 
also associated to increased proliferation, migration, survival or chemoresistance with unknown 
consequences for human tumor progression. Membrane depolarization has shown to promote cancer cell 
proliferation and migration independently of Ca2+ levels.  
 
Glossary 
Cav channels: voltage-gated Ca
2+ channels, activated by membrane depolarization.  A large family including 
Cav1 (4 isoforms, also called L-type channels), Cav2 (3 isoforms, including P/Q-type, N-type and R-type Ca
2+ 
channels) and Cav3 channels (3 isoforms, also called T-type Ca
2+ channels, TTCC). 
EC50: half maximal effective concentration, the drug concentration at which 50% of the maximum effect (on 
viability) is produced. This term is equivalent to GI50, as the drug concentration at which 50% of growth 
inhibition is produced. 
Gating: refers to the conformational changes experienced by ion channels leading to opening (activation), 
closing (deactivation) or to a non-conductive, refractory state (inactivation). 
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GBM: Glioblastoma Multiforme, a brain cancer characterized by high cell proliferation, invasivity and tumor 
cell infiltration into the surrounding brain parenchyma and angiogenesis. 
HVA: high voltage-activated. Channels activated by strong depolarization. 
Holding potential: membrane potential before test pulses, whose values are fixed by the voltage-clamp 
technique. 
IC50: half maximal inhibitory concentration, the drug concentration at which 50% of the maximum 
inhibition/block (on Ca2+ channels in this article) is produced  
Kv channels: voltage-gated K
+ channels, activated by membrane depolarization. 
LTCC: L-type Ca2+ channels. Belong to the Cav channels family and are activated by strong membrane 
depolarization. 
LVA: Low voltage-activated. Channels activated by weak depolarization, such as T-type Ca2+ channels.  
Modulated receptor theory: explains state-dependent block by proposing that a drug can bind to the drug 
receptor regardless of the state of the targeted ion channel, but its binding affinity in each state is 
different. An alternative explanation is provided by the is the guarded  receptor theory, suggesting that the 
affinity of drug binding to ion channels is state-independent, but is the access of the drug to the binding 
site that depends on channel conformation 
Nav channels: voltage-gated Na
+ channels, activated by membrane depolarization. 
State-dependence: when drug affinity/access depends on the gating state of the channel 
(resting/activated/inactivated). 
Steady-state activation/inactivation curves: curves illustrating the voltage dependence for channel 
activation and inactivation under stationary-state conditions (devoid of time-dependence). Steady-state 
activation is achieved by applying sufficiently long (typically > 50 ms) depolarizing test pulses (by the 
voltage clamp technique) for the channels to reach the open state. Steady-state inactivation is that 
achieved from the closed states through long-lasting prepulses (voltage pulses applied prior to the test 
pulse applied with the voltage-clamp technique, typically > 1 s) at subthreshold potentials. Steady-state 
activation/inactivation curves are fit by first-order Boltzmann functions. 
Use-dependence: when drug affinity/access correlates positively with the frequency of stimulation (i.e. 
membrane depolarizing stimuli), thus it is suggestive of drug binding to open and/or inactivated channels. 
Window currents: currents resulting from channels permanently open at steady potentials (resting 
membrane potentials in excitable cells), due to the overlap between steady-state inactivation and 
activation curves. 
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Table 1: potencies of TTCC block and cancer cell viability reduction of tetralol and 3,4 dihydroquinazoline derivatives 
 
Compound IC50 or Kd (M) GI50 on cancer cells (M) , 24-72 h 
 
 
Mibefradil 
 
0.2-1.3 (Cav3.1 expressed in HEK293)
 [71] [72] [116] [117] 
0.1-0.9 (Cav3.2 expressed in HEK 293) [58] [62] [118] 
0.1 (native TTCC of rat Purkinje neurons)[119]  
0.6 (native TTCC of dorsal root ganglion neurons [120] 
1.0 (native TTCC of bovine adrenal fasciculata cells) [63] 
1.2 (native TTCC of pulmonary microvascular endothelial cells) [121] 
3.3 (HCT116 colon carcinoma) [104] 
3.5 (U251 GBM) [105] 
20.5-24.3 (ovarian cancer cell lines) [71] 
24.8 (A549 lung adenocarcinoma) [72] 
31.4 (A549 lung adenocarcinoma) [116] 
NNC-55-0396 
 
< 1 (30-60 min)-10.1 (3 min) (Cav3.1 expressed in HEK293)
 [55] 2.1-2.9 (MCF-7 and MDA-MB-231  breast cancer cells) [32] 
4.8/5.3 (A2780/HO8910 ovarian carcinoma/adenocarcinoma) [33] 
KYS05090 0.3 (Cav3.1 expressed in HEK293)[72] 4.1 (A549 lung adenocarcinoma) [72]
 
KYS05090S, KCP10043F 0.5, 0.9 (Cav3.1 expressed in HEK293) [116] 
 
4.7, 7.3 (A549 lung adenocarcinoma) [116] 
 
5b, 6b,6c, BK10040, 8 0.5-1.8 (Cav3.1 expressed in HEK293) [72] 2.3-20.7 (A549 lung adenocarcinoma)
 [72] 
KYS05042, KYS05043, KYS05046, 
KYS05047, KYS05048, KYS05055, 
KYS05056, KYS05057, KYS05065, 
KYS05080, KYS05085, KYS05089, 
KYS05090 
 
0.04-1.0 (Cav3.1 expressed in HEK293) [68] 
 
 
 
0.17->100 M (A549 lung  adenocarcinoma) [68] 
KYS05090, 6a, 6c, 6d, 6f, 6g, 6h 0.3-0.6 (Cav3.1 expressed in HEK293) [71] 2.3-9.8 (SK-OV-3 epithelial ovarian cancer) [71] 
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Table 2: Effects of tetralols and 3,4-dihydroquinazolines on cell pathways/processes  
Drug Effects on membrane 
potential 
Effects on intracellular Ca2+ Effects on intracellular pathways/processes   
 
 
Mibefradil 
 
 
hyperpolarization [75] 
depolarization [78] [76] 
[77] 
 
 
triggered  Ca2+ release from ER and 
increased Ca2+ cytosolic concentration 
[92][93] 
 
increase of  P38-MAPK signaling [104] 
reduction of Akt/PkB  signaling [105] 
induction of caspase3/7-dependent apoptosis [104][105] 
induction of  caspase 3/9-dependent apoptosis [103][78]  
mTOR inhibition [105][122] 
induction of the unfolded protein response [103] 
deregulation of macroautophagy [103][122]  
upregulation  of p27(KIP1) and BAX [122] 
 
NNC-55-0396 N.D. triggered Ca2+-release from ER and 
increased Ca2+ cytosolic concentration  
[93] 
 
N.D. 
 
KYS05047 N.D. decreased cytosolic Ca2+ concentration 
[98] 
 
upregulation  of p27(KIP1) [98] 
KYS05090 N.D. decreased  cytosolic Ca2+ concentration 
[99] 
 
generation of ROS and  induction of macroautophagy [99] 
induction of caspase-3 dependent  apoptosis [99] 
 
N.D.: Not Determined. 
 
 
 
 
Highlights  
 T-type Ca2+ channels (TTCC) play a role in membrane excitability, and the development of selective 
TTCC pharmacological blockers for neurological conditions such as pain, epilepsy, tremor, ataxia 
and insomnia is an active area of research.  
 TTCC also enable sustained Ca2+ entry (known as window currents) which facilitates G1-S transition 
and appears necessary for survival of proliferating cells. Pharmacological targeting of TTCC is 
currently explored as a chemotherapeutic option, and different compounds with TTCC blocking 
ability have shown to reduce cancer cell viability in vitro.  
 Two classes of TTCC blockers, tetralols and dihydroquinazolines (DHQ), have shown to slow 
Glioblastoma progression in mouse models, and clinical trials are performed to assess the optimal 
dosing and tolerance of tetralol mibefradil in Glioblastoma Multiforme patients. 
 A majority of TTCC blockers (including tetralols and DHQ) display a state-dependent affinity which 
implies a low-potency block on permanently open TTCC contributing window currents, and are 
cytotoxic to cancer cells at higher concentrations than those required for channel block. Reported 
off-target effects of tetralols, including membrane potential shifts and Ca2+ mobilization from the 
endoplasmic reticulum, are largely unexplored for other TTCC blockers. 
 Gene silencing experiments highlight the value of targeting TTCC in neurological diseases and 
cancer, and can be used to evaluate the pharmacological specificity of curren and novel 
compounds.  
 
Outstanding Questions   
 Available TTCC blockers exhibit increased affinity for the closed and/or inactivated states; 
to what extent does it imply a low-potency block of window currents?  
 Are there any cytostatic and/or cytotoxic effects on cancer cells of tetralols and DHQ at 
concentrations compatible with their reported IC50s?  
 Are cytostatic/cytotoxic effects of TTCC blockers used at supramaximal concentrations due 
to off-target effects?  
 Can state-dependent, highly-potent TTCC blockers -developed in the context of 
neurological research- be repurposed for cancer treatment?  
 Gene silencing experiments show that depletion of Cav3.1 or Cav3.2 affects negatively the 
viability of cancer cells in vitro; to what extent the cellular pathways modulated by channel 
knockdown coincide with those triggered by pharmacological blockers?  
 What are the effects of the selective knockdown of TTCC isoforms in preclinical in vivo 
models?  
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